Literature DB >> 30198300

Evaluating Quality of Life in Patients With Meniere's Disease Treated as Migraine.

Yaser Ghavami1, Yarah M Haidar1, Omid Moshtaghi1, Harrison W Lin1, Hamid R Djalilian1,2.   

Abstract

OBJECTIVE: : To evaluate the change in quality of life (QOL) of patients with Meniere's disease (MD) after treatment with migraine prophylaxis therapy.
METHODS: : Patients with definite MD were given the Meniere's Disease Outcomes Questionnaire-Retrospective (MDOQ-R) after migraine prophylactic therapy to assess QOL. Changes in physical, emotional, and social parameters affected by MD were calculated, along with a global pre- and posttreatment QOL scores.
RESULTS: : The MDOQ-R was given to 27 consecutive patients with definite MD. Patients who had at least an 18-month follow-up were included, resulting in 25 questionnaires. The mean change in QOL score was 25 ± 16 (range, -3 to 55), P = .02. Quality of life was improved in 23 (92%) of the respondents in every metric measured, unchanged in 1 (4%), and poorer in 1 (4%) of patients after migraine prophylaxis treatment.
CONCLUSIONS: : Majority of MD patients who had all failed diuretic therapy responded positively to medications used for migraine prophylaxis, as indicated by a significant improvement in QOL. This study may further suggest a correlation between the pathophysiologic basis of disease in MD and vestibular migraine. Patients with MD may be successfully managed with medications intended to treat migraine.

Entities:  

Keywords:  Meniere’s disease; dizziness; migraine; quality of life; vertigo; vestibular migraine

Mesh:

Substances:

Year:  2018        PMID: 30198300     DOI: 10.1177/0003489418799107

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  9 in total

1.  Successful treatment of a child with definite Meniere's disease with the migraine regimen.

Authors:  Mehdi Abouzari; Arash Abiri; Hamid R Djalilian
Journal:  Am J Otolaryngol       Date:  2019-02-18       Impact factor: 1.808

2.  Vestibular drop attacks in Ménière's disease and its association with migraine.

Authors:  Ilmari Pyykkö; Nora Pyykkö; Vinaya Manchaiah
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-17       Impact factor: 2.503

3.  A hypothetical proposal for association between migraine and Meniere's disease.

Authors:  Brooke Sarna; Mehdi Abouzari; Harrison W Lin; Hamid R Djalilian
Journal:  Med Hypotheses       Date:  2019-10-12       Impact factor: 1.538

4.  Vertigo without cochlear symptoms: vestibular migraine or Menière disease?

Authors:  Roberto Teggi; Marco Familiari; Omar Gatti; Mario Bussi
Journal:  Neurol Sci       Date:  2021-03-25       Impact factor: 3.307

5.  Treatment of Long-term Sudden Sensorineural Hearing Loss as an Otologic Migraine Phenomenon.

Authors:  Khodayar Goshtasbi; Janice T Chua; Adwight Risbud; Brooke Sarna; Shahrnaz Jamshidi; Mehdi Abouzari; Hamid R Djalilian
Journal:  Otol Neurotol       Date:  2021-08-01       Impact factor: 2.619

Review 6.  Cochlear implantation in patients with Meniere's disease: A systematic review.

Authors:  Vincent M Desiato; Jaimin J Patel; Shaun A Nguyen; Ted A Meyer; Paul R Lambert
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-04-23

7.  Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss.

Authors:  Mehdi Abouzari; Khodayar Goshtasbi; Janice T Chua; Donald Tan; Brooke Sarna; Tina Saber; Harrison W Lin; Hamid R Djalilian
Journal:  Laryngoscope       Date:  2020-04-03       Impact factor: 3.325

8.  Efficacy of Multi-Modal Migraine Prophylaxis Therapy on Hyperacusis Patients.

Authors:  Mehdi Abouzari; Donald Tan; Brooke Sarna; Yaser Ghavami; Khodayar Goshtasbi; Erica M Parker; Harrison W Lin; Hamid R Djalilian
Journal:  Ann Otol Rhinol Laryngol       Date:  2019-12-01       Impact factor: 1.547

9.  Tinnitus and Subjective Hearing Loss are More Common in Migraine: A Cross-Sectional NHANES Analysis.

Authors:  Khodayar Goshtasbi; Mehdi Abouzari; Adwight Risbud; Navid Mostaghni; Ethan G Muhonen; Elaine Martin; Hamid R Djalilian
Journal:  Otol Neurotol       Date:  2021-10-01       Impact factor: 2.619

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.